{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:15:54Z","timestamp":1768608954060,"version":"3.49.0"},"reference-count":37,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Clozapine is a potent antipsychotic mainly used in treatment-resistant schizophrenia. Its clinical efficacy in elderly patients is sparsely documented. Elderly patients achieve higher plasma levels of clozapine, requiring careful dose adjustments to minimize side effects such as sedation, hypotension, metabolic disorders, and notably pneumonia and ileus \u2013 both associated with significant mortality. Individualized dosing and regular monitoring are essential to ensure optimal safety and tolerability in elderly patients receiving clozapine, as argued in this review.<\/jats:p>","DOI":"10.61409\/v04250302","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:06:41Z","timestamp":1768219601000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Clozapine for elderly people with schizophrenia"],"prefix":"10.61409","author":[{"given":"Philip Lindblad","family":"Thorsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper Krogh","family":"Lauridsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Azuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Reeves S, Bertrand J, Obee SJ, et al. A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status. Br J Clin Pharmacol. 2024;90(1):135-145. https:\/\/doi.org\/10.1111\/bcp.15691","DOI":"10.1111\/bcp.15691"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Ismail Z, Wessels AM, Uchida H, et al. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry. 2012;20(1):53-60. https:\/\/doi.org\/10.1097\/JGP.0b013e3182118318","DOI":"10.1097\/JGP.0b013e3182118318"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Liu T, Gao P, Xie C, et al. Study on the daily dose and serum concentration of clozapine in psychiatric patients and possible influencing factors of serum concentration. BMC Psychiatry. 2023;23(1):596. https:\/\/doi.org\/10.1186\/s12888-023-05078-z","DOI":"10.1186\/s12888-023-05078-z"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Castberg I, Westin AA, Skogvoll E, et al. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand. 2017;136(5):455-464. https:\/\/doi.org\/10.1111\/acps.12794","DOI":"10.1111\/acps.12794"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Mach A, Wnorowska A, Siwek M, et al. Clinical and pharmacological factors influencing serum clozapine and norclozapine levels. Front Pharmacol. 2024;15:1356813. https:\/\/doi.org\/10.3389\/fphar.2024.1356813","DOI":"10.3389\/fphar.2024.1356813"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Flanagan RJ, Hunter S, Obee SJ, et al. Clozapine: dose, sex, ethnicity, smoking habit, age, body weight, and plasma clozapine and N-desmethylclozapine (norclozapine) concentrations in clinical practice. J Clin Psychopharmacol. 2023;43(2):131-138. https:\/\/doi.org\/10.1097\/JCP.0000000000001653","DOI":"10.1097\/JCP.0000000000001653"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry. 1999;60(1):36-40. https:\/\/doi.org\/10.4088\/JCP.v60n0108","DOI":"10.4088\/JCP.v60n0108"},{"issue":"5","key":"ref7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/(SICI)1099-1166(199705)12:5<553::AID-GPS547>3.0.CO;2-U","article-title":"Outcome of clozapine therapy for elderly patients with refractory primary psychosis","volume":"12","author":"Sajatovic","year":"1997","unstructured":"Sajatovic M, Jaskiw G, Konicki PE, et al. Outcome of clozapine therapy for elderly patients with refractory primary psychosis. Int J Geriatr Psychiatry. 1997;12(5):553-558","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Pridan S, Swartz M, Baruch Y, et al. Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. Int Psychogeriatr. 2015;27(1):131-134. https:\/\/doi.org\/10.1017\/S1041610214001756","DOI":"10.1017\/S1041610214001756"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Vieira JCM, Reis EA, Prata WM, et al. Effectiveness of clozapine compared to nonclozapine antipsychotics in older adults with schizophrenia in Brazil in a 16-year follow-up. Am J Geriatr Psychiatry. 2025;33(11):1184-1196. https:\/\/doi.org\/10.1016\/j.jagp.2025.02.016","DOI":"10.1016\/j.jagp.2025.02.016"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Tiihonen J, L\u00f6nnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627. https:\/\/doi.org\/10.1016\/S0140-6736(09)60742-X","DOI":"10.1016\/S0140-6736(09)60742-X"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Hayes RD, Downs J, Chang CK, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull. 2015;41(3):644-655. https:\/\/doi.org\/10.1093\/schbul\/sbu120","DOI":"10.1093\/schbul\/sbu120"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Barak Y, Wittenberg N, Naor S, et al. Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr Psychiatry. 1999;40(4):320-325. https:\/\/doi.org\/10.1016\/S0010-440X(99)90134-7","DOI":"10.1016\/S0010-440X(99)90134-7"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Sajatovic M, Ramirez LF, Garver D, et al. Clozapine therapy for older veterans. Psychiatr Serv. 1998;49(3):340-344. https:\/\/doi.org\/10.1176\/ps.49.3.340","DOI":"10.1176\/ps.49.3.340"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Siskind D, Sharma M, Pawar M, et al. Clozapine levels as a predictor for therapeutic response: a systematic review and meta-analysis. Acta Psychiatr Scand. 2021;144(5):422-432. https:\/\/doi.org\/10.1111\/acps.13361","DOI":"10.1111\/acps.13361"},{"issue":"6","key":"ref15","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40262-023-01247-1","article-title":"Association between clozapine plasma concentrations and treatment response: a systematic review, meta-analysis and individual participant data meta-analysis","volume":"62","author":"Tralongo","year":"2023","unstructured":"Tralongo F, Konecki C, Feliu C, et al. Association between clozapine plasma concentrations and treatment response: a systematic review, meta-analysis and individual participant data meta-analysis. Clin Pharmacokinet. 2023;62(6):807-818.","journal-title":"Clin Pharmacokinet"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1007\/s40262-023-01247-1","DOI":"10.1007\/s40262-023-01247-1"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Gr\u00fcnder G. Editorial to consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry. 2018;51(1-02):5-6. https:\/\/doi.org\/10.1055\/s-0043-118103","DOI":"10.1055\/s-0043-118103"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Bogers JPAM, Schulte PFJ, Broekman TG, et al. Feasibility and effect of increasing clozapine plasma levels in long-stay patients with treatment-resistant schizophrenia. J Clin Psychopharmacol. 2023;43(2):97-105. https:\/\/doi.org\/10.1097\/JCP.0000000000001657","DOI":"10.1097\/JCP.0000000000001657"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Meyer JM, Stahl SM. The clozapine handbook. Stahl's Handbooks. New edition. Cambridge: Cambridge University Press, 2019","DOI":"10.1017\/9781108553575"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1017\/9781108553575","DOI":"10.1017\/9781108553575"},{"issue":"3","key":"ref21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00213-020-05746-y","article-title":"A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions","volume":"238","author":"Tan","year":"2021","unstructured":"Tan MSA, Honarparvar F, Falconer JR, et al. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. Psychopharmacology (Berl). 2021;238(3):615-637.","journal-title":"Psychopharmacology (Berl)"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1007\/s00213-020-05746-y","DOI":"10.1007\/s00213-020-05746-y"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Skokou M, Karavia EA, Drakou Z, et al. Adverse drug reactions in relation to clozapine plasma levels: a systematic review. Pharmaceuticals (Basel). 2022;15(7):817. https:\/\/doi.org\/10.3390\/ph15070817","DOI":"10.3390\/ph15070817"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Williams AM, Park SH. Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs. 2015;29(2):101-111. https:\/\/doi.org\/10.1007\/s40263-014-0222-y","DOI":"10.1007\/s40263-014-0222-y"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Schoretsanitis G, Kuzin M, Kane JM, et al. Elevated clozapine concentrations in clozapine-treated patients with hypersalivation. Clin Pharmacokinet. 2021;60(3):329-335. https:\/\/doi.org\/10.1007\/s40262-020-00944-5","DOI":"10.1007\/s40262-020-00944-5"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Partanen JJ, H\u00e4pp\u00f6l\u00e4 P, K\u00e4mpe A, et al. High burden of ileus and pneumonia in clozapine-treated individuals with schizophrenia: a Finnish 25-year follow-up register study. Am J Psychiatry. 2024;181(10):879-892. https:\/\/doi.org\/10.1176\/appi.ajp.20230744","DOI":"10.1176\/appi.ajp.20230744"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"De Las Cuevas C, Sanz EJ, de Leon J. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: comparing the top four reporting countries (US, UK, Canada and Australia). Schizophr Res. 2024;268:165-174.","DOI":"10.1016\/j.schres.2023.05.004"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1016\/j.schres.2023.05.004","DOI":"10.1016\/j.schres.2023.05.004"},{"issue":"2","key":"ref29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/17512433.2021.1877135","article-title":"An update on the complex relationship between clozapine and pneumonia","volume":"14","author":"Schoretsanitis","year":"2021","unstructured":"Schoretsanitis G, Ruan CJ, Rohde C, et al. An update on the complex relationship between clozapine and pneumonia. Expert Rev Clin Pharmacol. 2021;14(2):145-149.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1080\/17512433.2021.1877135","DOI":"10.1080\/17512433.2021.1877135"},{"issue":"6","key":"ref31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/ACI.0000000000000592","article-title":"Clozapine-associated secondary antibody deficiency","volume":"19","author":"Ponsford","year":"2019","unstructured":"Ponsford MJ, Pecoraro A, Jolles S. Clozapine-associated secondary antibody deficiency. Curr Opin Allergy Clin Immunol. 2019;19(6):553-562.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1097\/ACI.0000000000000592","DOI":"10.1097\/ACI.0000000000000592"},{"issue":"9","key":"ref33","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00702-024-02818-7","article-title":"Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 2016","volume":"131","author":"Bleich","year":"2024","unstructured":"Bleich L, Grohmann R, Greil W, et al. Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 2016. J Neural Transm (Vienna). 2024;131(9):1117-1134.","journal-title":"J Neural Transm (Vienna)"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1007\/s00702-024-02818-7","DOI":"10.1007\/s00702-024-02818-7"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Groenewald FCE, Kok RM. Side effects of clozapine in older adults with treatment-resistant schizophrenia compared to younger adults. Int J Geriatr Psychiatry. 2024;39(1):e6051. https:\/\/doi.org\/10.1002\/gps.6051","DOI":"10.1002\/gps.6051"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"O'Connor DW, Sierakowski C, Chin LF, Singh D. The safety and tolerability of clozapine in aged patients: a retrospective clinical file review. World J Biol Psychiatry. 2010;11(6):788-791. https:\/\/doi.org\/10.3109\/15622975.2010.488273","DOI":"10.3109\/15622975.2010.488273"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:56:31Z","timestamp":1768571791000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V04250302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":37,"URL":"https:\/\/doi.org\/10.61409\/v04250302","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}